Pharmacodynamics and pharmacokinetics of ketoprofen enantiomers in sheep

American Journal of Veterinary Research

Volumn 62, Issue 1, 2001, Pages 77-86

  Arifah, Abdul K ^a,b   Landoni, Maria F ^a,c   Frean, Stephen P ^a   Lees, Peter ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

KETOPROFEN;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHIRALITY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; ENANTIOMER; NONHUMAN; PROSTAGLANDIN SYNTHESIS; SHEEP;

EID: 0035139447     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2001.62.77     Document Type: Article

References (40)

1. Julou L, Guyonnet JC, Ducrot RJ, et al. Ketoprofen (19.583R.P.) (2-(3-benzoylphenyl-propionic acid) - main pharmacological properties. Outline of toxicological and pharmacokinetic data. Scand J Rheumatol 1976(suppl);14:33-44.
2. Sigurdsson GH, Youssef H. Amelioration of respiratory and circulatory changes in established endotoxic shock by ketoprofen. Acta Anaesthesiol Scand 1994;38:33-39.
3. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids - a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693-704.
4. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
5. Caldwell J, Hutt AJ, Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropi-onic acids and their biological consequences. Biochem Pharmacol 1988:37:105-114.
6. Sallustio BC, Purdie YJ, Whitehead AG, et al. The disposition of ketoprofen enantiomers in man. Br J Clin Pharmacol 1988; 26:765-770.
7. Evans, AM Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992;42:237-256.
8. Delatour P, Benoit E, Bourdin M, et al. Enantioselectivite comparee de la disposition de deux anti-inflammatories non steroidiens, le ketoprofene et le carprofene, chez l'homme et l'animal. Bull Acad Nationale Med 1993;177:515-527.
9. Jaussaud P, Bellon C, Besse S, et al. Enantioselective pharmacokinetics of ketoprofen in horses. J Vet Pharmacol Ther 1993;16: 373-376.
10. Landoni MF; Lees P Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. Equine Vet J 1995;27:247-256.
11. Suesa N, Fernandez MF, Gutierrez M, et al. Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993;5:589-595.
12. Williams KM, Hall I, Day R, et al. Nonsteroidal anti-inflammatory drugs and their enantiomers. In: Lewis AJ, Frust DE. eds. Non-steroidal anti-inflammatory drugs (mechanisms and clinical uses). New York: Mercel Dekker Inc, 1994;127-141.
13. Landoni MF, Cunningham FM, Lees P. Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. J Vet Pharmacol Ther 1995;18:315-324.
14. Landoni MF, Lees P. Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. Chirality 1995;7: 586-597.
15. Emau P, Giri SN, Bruss ML, Zia S. Ibuprofen prevents Pasteurella hemolytica endotoxin-induced changes in plasma prostanoids and serotonin, and fever in sheep. J Vet Pharmacol Ther 1985;8:53-361.
16. Foster RT, Jamali G. Stereoselective pharmacokinetics of ketoprofen in the rat. Drug Metab Dispos 1988;16:623-626.
17. Higgins AJ, Lees P. Arachidonic acid metabolites in carrageenan-induced equine inflammatory exudate. J Vet Pharmacol Ther 1984;7:65-72.
18. Satterwhite KJ, Boudinot FD. Pharmacokinetics of ketoprofen in rats: effects of age and dose. Biopharm Drug Dispos 1992;13:197-212.
19. Dahlstrom B, Paalzow L, Segre G, Agran J. Relationship between morphine pharmacokinetics and analgesia. J Pharmacol Biopharm 1978;6:41-53.
20. Holford N, Sheiner L. Understanding the dose-effect relationship: clinical application to pharmacokinetics-pharmacodynam-ic models. Clin Pharmacol Kinet 1981;6:429-453.
21. Holford N, Sheiner L. Kinetics of pharmacologic response. Pharmacol Therap 1982;16:143-166.
22. Fuseau E, Sheiner L. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a non-parametric pharmacodynamic model. Clin Pharmacol Ther 1984;35:733-741.
23. Sheiner L. Modeling pharmacodynamics: parametric and non-parametric approaches. In: Rowland L, Steiner J, eds. Variability in drug therapy: description, estimation and control. New York: Raven Press, 1985;139-152.
24. Beck W, Geisslinger G, Engler H, et al. Pharmacokinetics of ibuprofen enantiomers in dogs. Chirality 1991;3:165-169.
25. Abas A, Meffin PJ. Enantioselective disposition of 2-arylpropionic acid non-steroidal anti-inflammatory drugs. IV. Ketoprofen disposition. J Pharmacol Exp Ther 1987;240:637-641.
26. Rendic S, Albic-Kolbah T, Kajfez F, et al. Stereoselective binding of (+) and (-)-alpha-(benzoylphenylpropionic) acid (ketoprofen) to human serum albumin. Farmaco Edizione Scientifica 1980;35:51-59.
27. Hayball PJ, Nation RL, Bochner F, et al. The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. Brit J Clin Pharmacol 1993; 36:185-193.
28. Sams R, Gerken DF, Ashcraft SM. Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. J Vet Pharmacol Ther 1995;18:108-116.
29. Foster RT, Jamali F, Russell AS, et al. Pharmacokinetics of ketoprofen enantiomers in healthy subjects after single and multiple doses. J Pharm Sci 1988;77:70-73.
30. Landoni MF, Lees P. Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in the horse. J Vet Pharmacol Ther 1996;19:466-474.
31. Iwakawa S, Suganuma T, Lee SF, et al. Direct determination of diastereomeric carprofen glucuronides in human plasma and urine and preliminary measurements of stereoselective metabolic and renal elimination after oral administration of carprofen in man. Drug Metab Dispos 1989;17:414-419.
32. Owens JG, Kamerling SG, Barker SA. Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis. J Vet Pharmacol Ther 1995;18:187-195.
33. Hayball PJ, Nation RL, Bochner F. Enantioselective pharmacodynamics of the nonsteroidal anti-inflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. Chirality 1992;4:484-487.
34. Oelkers R, Neupert W, Williams KM, et al. Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. Br J Clin Pharmacol 1997;43:145-153.
35. Brune K, Geisslinger G, Menzel-soglowek S. Pure enantiomers of 2-arylpropionic acids: tools in pain research and improved drugs in rheumatology. J Clin Pharmacol 1992;32: 944-952.
36. Higgins AJ, Lees P, Taylor JB. Influence of phenylbutazone on eicosanoid levels in equine inflammatory exudate. Cornell Vet 1984;72:198-207.
37. 2 production in equine inflammation. Res Vet Sci 1984;37:347-349.
38. Higgins AJ, Lees P, Taylor JBO, et al. Flunixin meglumine: quantitative determination in and effects on composition of equine inflammatory exudate. Br Vet J 1986;142:163-169.
39. Lees P, Higgins AJ. Effects of a phenylbutazone paste in ponies: Model of acute nonimmune inflammation. Am J Vet Res 1986; 47:2359-2363.
40. Lees P, Sedgwick AD, Higgins AJ, et al. Pharmacodynamics and pharmacokinetics of meloxicam in the horse. Br Vet J 1991;147: 97-108.